Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBIT Margin: 2011-2025

Historic EBIT Margin for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to 11.79%.

  • Aytu Biopharma's EBIT Margin fell 522.00% to 10.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.19%, marking a year-over-year decrease of 968.00%. This contributed to the annual value of 11.79% for FY2025, which is 845.00% down from last year.
  • Aytu Biopharma's EBIT Margin amounted to 11.79% in FY2025, which was down 252.71% from 3.34% recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's EBIT Margin ranged from a high of 3.34% in FY2024 and a low of 113.69% during FY2022.
  • Its 3-year average for EBIT Margin is 10.34%, with a median of 11.79% in 2025.
  • Per our database at Business Quant, Aytu Biopharma's EBIT Margin crashed by 2,400bps in 2022 and then soared by 9,780bps in 2023.
  • MRY analysis of 5 years shows Aytu Biopharma's EBIT Margin stood at 89.70% in 2021, then decreased by 27bps to 113.69% in 2022, then skyrocketed by 86bps to 15.89% in 2023, then surged by 79bps to 3.34% in 2024, then crashed by 253bps to 11.79% in 2025.
  • Its EBIT Margin stands at 11.79% for FY2025, versus 3.34% for FY2024 and 15.89% for FY2023.